Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lung Adenocarcinoma Treatment Market

Lung Adenocarcinoma Treatment Market Trends

Report ID: GMI11125
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Lung Adenocarcinoma Treatment Market Trends

Market growth is significantly propelled by the emergence of new and effective treatments, particularly targeted therapies and immunotherapies. According to the National Cancer Institute, the adoption of these therapies has increased by 15% annually over the past five years. These therapies are gaining traction not only for their ability to improve patient outcomes but also for their reduced side effects compared to traditional chemotherapy.
Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), focus on specific molecules that influence the growth and spread of cancer cells.
For instance, the American Cancer Society reports that these therapies have shown a 25% improvement in survival rates for patients with NSCLC. Their proven efficacy in treating NSCLC has established them as the standard of care for select patients with advanced NSCLC.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The lung adenocarcinoma treatment market size was valued at around USD 5.1 billion in 2023 and is estimated to grow at 10.5% CAGR from 2024 to 2032, driven by the rising incidence of lung cancer.

The stage IV lung adenocarcinoma treatment segment was valued at USD 3.1 billion in 2023, driven by the growing adoption of advanced treatment options like targeted therapies and immunotherapies.

North America lung adenocarcinoma treatment market is forecasted to reach USD 5.7 billion by 2032, driven by the introduction of novel therapies.

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd among others.